Aclaris Therapeutics Inc (NASDAQ:ACRS) – Analysts at William Blair lowered their FY2019 EPS estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Monday, March 18th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings of ($2.98) per share for the year, down from their prior estimate of ($2.93). William Blair also issued estimates for Aclaris Therapeutics’ FY2020 earnings at ($2.67) EPS.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Monday, March 18th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.03). The company had revenue of $3.67 million for the quarter, compared to the consensus estimate of $4.40 million. Aclaris Therapeutics had a negative return on equity of 72.13% and a negative net margin of 1,315.41%.
Shares of NASDAQ:ACRS opened at $6.27 on Thursday. The firm has a market cap of $285.17 million, a P/E ratio of -1.56 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 6.57 and a quick ratio of 6.48. Aclaris Therapeutics has a 12-month low of $5.49 and a 12-month high of $21.97.
A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its holdings in Aclaris Therapeutics by 43.8% during the 4th quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock worth $26,759,000 after acquiring an additional 1,103,423 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Aclaris Therapeutics by 71.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,278,364 shares of the biotechnology company’s stock worth $16,837,000 after acquiring an additional 950,781 shares during the period. Sofinnova Investments Inc. grew its holdings in Aclaris Therapeutics by 24.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,911,573 shares of the biotechnology company’s stock worth $14,127,000 after acquiring an additional 372,093 shares during the period. Broadfin Capital LLC acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $13,875,000. Finally, MFN Partners Management LP acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $11,085,000. Hedge funds and other institutional investors own 94.97% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Featured Article: What are no-load funds?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.